Imaging Tumor Burden in the Brain with 89Zr-Transferrin

Journal of Nuclear Medicine

Carl Campos¹  Ingo K. Mellinghoff¹  Samuel L. Rice¹  Charles L. Sawyers¹  Michael G. Doran¹  Jason S. Lewis¹  Michael J. Evans¹  Sean D. Carlin¹  Sarah M. Cheal¹  Jason P. Holland¹ 

关键词: ⁸⁹Zr;    transferrin;    positron emission tomography;    glioma;    molecular imaging;   

DOI  :  10.2967/jnumed.112.109777

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

A noninvasive technology that indiscriminately detects tumor tissue in the brain could substantially enhance the management of primary or metastatic brain tumors. Although the documented molecular heterogeneity of diseases that initiate or eventually deposit in the brain may preclude identifying a single smoking-gun molecular biomarker, many classes of brain tumors are generally avid for transferrin. Therefore, we reasoned that applying a radiolabeled derivative of transferrin (89Zr-labeled transferrin) may be an effective strategy to more thoroughly identify tumor tissue in the brain, regardless of the tumor’s genetic background. Methods: Transferrin was radiolabeled with 89Zr, and its properties with respect to human models of glioblastoma multiforme were studied in vivo. Results: In this report, we show proof of concept that 89Zr-labeled transferrin (89Zr-transferrin) localizes to genetically diverse models of glioblastoma multiforme in vivo. Moreover, we demonstrate that 89Zr-transferrin can detect an orthotopic lesion with exceptional contrast. Finally, the tumor-to-brain contrast conferred by 89Zr-transferrin vastly exceeded that observed with 18F-FDG, currently the most widely used radiotracer to assess tumor burden in the brain. Conclusion: The results from this study suggest that 89Zr-transferrin could be a broadly applicable tool for identifying and monitoring tumors in the brain, with realistic potential for near-term clinical translation.

【 授权许可】

Unknown